Document is current
Any future updates will be listed below
-
Authors
Jani, Saumya
Pulliam, Thomas
Kumar, Nandita
Jojic, Ana
Bhakuni, Rashmi
Newell, Evan
Nghiem, Paul
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02267603 at ClinicalTrials.govnct02267603 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
https://doi.org/10.1136/jitc-2021-002478
1018 A transcriptional signature shared by circulating cancer-specific CD8 T cells
https://doi.org/10.1136/jitc-2023-sitc2023.1018
1045 High dimensional profiling of merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy
https://doi.org/10.1136/jitc-2022-sitc2022.1045
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
https://doi.org/10.1136/jitc-2021-002478
1018 A transcriptional signature shared by circulating cancer-specific CD8 T cells
https://doi.org/10.1136/jitc-2023-sitc2023.1018
1045 High dimensional profiling of merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy
https://doi.org/10.1136/jitc-2022-sitc2022.1045
- License Information
